Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

The definitive diagnosis of melanocytic neoplasia using solely histopathologic evaluation can be challenging. Novel techniques that objectively confirm diagnoses are needed. This study details the development and validation of a melanoma prediction model from spatially resolved multivariate protein expression profiles generated by imaging mass spectrometry (IMS).

[1]  Ryanne A. Brown,et al.  PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features , 2020, Journal of cutaneous pathology.

[2]  K. Linos,et al.  Concordance Analysis of the 23-Gene Expression Signature (myPath Melanoma) With Fluorescence In Situ Hybridization Assay and Single Nucleotide Polymorphism Array in the Analysis of Challenging Melanocytic Lesions: Results From an Academic Medical Center. , 2020, The American Journal of dermatopathology.

[3]  D. Elder,et al.  Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. , 2020, Personalized medicine.

[4]  K. Busam,et al.  Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors , 2020, The American journal of surgical pathology.

[5]  A. Andea.  Updates on molecular diagnostic assays in melanocytic pathology , 2020 .

[6]  L. Lowe,et al.  DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach , 2020, Modern Pathology.

[7]  A. Andea,et al.  Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis , 2020, Modern Pathology.

[8]  W. High,et al.  Immunohistochemistry utilization in the diagnosis of melanoma , 2020, Journal of cutaneous pathology.

[9]  R. Gueorguieva,et al.  Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma , 2019, Journal of cutaneous pathology.

[10]  Carsten Denkert,et al.  MALDI‐Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods , 2018, Proteomics. Clinical applications.

[11]  Jannis Teunissen,et al.  Tumor classification with MALDI-MSI data of tissue microarrays: A case study. , 2018, Methods.

[12]  K. Nehal,et al.  PRAME Expression in Melanocytic Tumors , 2018, American Journal of Surgical Pathology.

[13]  C. Lian,et al.  Molecular Testing for Cutaneous Melanoma: An Update and Review. , 2018, Archives of pathology & laboratory medicine.

[14]  R. Caprioli,et al.  Advanced Registration and Analysis of MALDI Imaging Mass Spectrometry Measurements through Autofluorescence Microscopy. , 2018, Analytical chemistry.

[15]  Richard M Caprioli,et al.  Next Generation Histology-Directed Imaging Mass Spectrometry Driven by Autofluorescence Microscopy. , 2018, Analytical chemistry.

[16]  E. Velazquez,et al.  Comparison of melanoma gene expression score with histopathology, fluorescence in situ hybridization, and SNP array for the classification of melanocytic neoplasms , 2018, Modern Pathology.

[17]  V. Adam,et al.  MALDI MSI of MeLiM melanoma: Searching for differences in protein profiles , 2017, PloS one.

[18]  K. Schey,et al.  MALDI (matrix assisted laser desorption ionization) Imaging Mass Spectrometry (IMS) of skin: Aspects of sample preparation. , 2017, Talanta.

[19]  E. Seeley,et al.  Proteomic Mass Spectrometry Imaging for Skin Cancer Diagnosis. , 2017, Dermatologic clinics.

[20]  M. Weinstock,et al.  Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study , 2017, British Medical Journal.

[21]  H. Kimbrell,et al.  Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[22]  R. Caprioli,et al.  Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms. , 2016, Journal of the American Academy of Dermatology.

[23]  J. Elmore,et al.  Achieving consensus for the histopathologic diagnosis of melanocytic lesions: use of the modified Delphi method , 2016, Journal of cutaneous pathology.

[24]  Danielle B. Gutierrez,et al.  Pathology interface for the molecular analysis of tissue by mass spectrometry , 2016, Journal of pathology informatics.

[25]  P. Marcorelles,et al.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma , 2015, Diagnostic Pathology.

[26]  R. Caprioli,et al.  Congenital nevi versus metastatic melanoma in a newborn to a mother with malignant melanoma – diagnosis supported by sex chromosome analysis and Imaging Mass Spectrometry , 2015, Journal of cutaneous pathology.

[27]  Matthew Hand,et al.  Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches. , 2015, Journal of the American Academy of Dermatology.

[28]  R. Caprioli,et al.  Histology-directed and imaging mass spectrometry: An emerging technology in ectopic calcification. , 2015, Bone.

[29]  C. Lian,et al.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update , 2015, Dermatopathology.

[30]  A. Gutin,et al.  Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma , 2015, Journal of cutaneous pathology.

[31]  A. Viale,et al.  A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation. , 2013, The Journal of molecular diagnostics : JMD.

[32]  Heinz Höfler,et al.  MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. , 2013, Clinical biochemistry.

[33]  S. South,et al.  Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements. , 2012, Archives of pathology & laboratory medicine.

[34]  R. Hofmann-Wellenhof,et al.  Agreement of Dermatopathologists in the Evaluation of Clinically Difficult Melanocytic Lesions: How Golden Is the ‘Gold Standard’? , 2012, Dermatology.

[35]  Richard M Caprioli,et al.  Imaging Mass Spectrometry—A New and Promising Method to Differentiate Spitz Nevi From Spitzoid Malignant Melanomas , 2012, The American Journal of dermatopathology.

[36]  R. Caprioli,et al.  Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of human skin proteomic signatures , 2011, Experimental dermatology.

[37]  Richard M Caprioli,et al.  Protein signatures for survival and recurrence in metastatic melanoma. , 2011, Journal of proteomics.

[38]  L. Cerroni,et al.  Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases , 2011, Modern Pathology.

[39]  R. Scolyer,et al.  Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? , 2011, Archives of pathology & laboratory medicine.

[40]  A. Enk,et al.  Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up , 2010, Modern Pathology.

[41]  M. Mihm,et al.  The dermal-based borderline melanocytic tumor: a categorical approach. , 2010, Journal of the American Academy of Dermatology.

[42]  L. Morrison,et al.  Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma , 2009, The American journal of surgical pathology.

[43]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[44]  Yu Shyr,et al.  Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.

[45]  P. Leboit,et al.  Histological Diagnosis of Nevi and Melanoma , 2004, Steinkopff.

[46]  R. Caprioli,et al.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. , 1997, Analytical chemistry.

[47]  W. Mooi,et al.  Quality assessment by expert opinion in melanoma pathology: experience of the Pathology Panel of the Dutch Melanoma Working Party , 1997, The Journal of pathology.

[48]  M. Tetzlaff,et al.  Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry. , 2017, Actas dermo-sifiliograficas.

[49]  D. Jukic,et al.  Discrepancies in dermatopathology diagnoses: the role of second review policies and dermatopathology fellowship training. , 2013, Journal of the American Academy of Dermatology.

[50]  Vladimir Vapnik,et al.  Support-vector networks , 2004, Machine Learning.